Talis Biomedical (TLIS) Price & Analysis

Q: What was Talis Biomedical’s price range in the past 12 months?

Talis Biomedical lowest stock price was $1.04 and its highest was $2.00 in the past 12 months.

Q: What is Talis Biomedical’s market cap?

Talis Biomedical’s market cap is $50.70M.

Q: When is Talis Biomedical’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: How were Talis Biomedical’s earnings last quarter?

Talis Biomedical released its earnings results on Aug 07, 2024. The company reported -$4.856 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.856.

Q: Is Talis Biomedical overvalued?

According to Wall Street analysts Talis Biomedical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Talis Biomedical pay dividends?

Talis Biomedical does not currently pay dividends.

Q: What is Talis Biomedical’s EPS estimate?

Talis Biomedical’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Talis Biomedical have?

Talis Biomedical has 1,822,820 shares outstanding.

Q: What happened to Talis Biomedical’s price movement after its last earnings report?

Talis Biomedical reported an EPS of -$4.856 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.222%.

Q: Which hedge fund is a major shareholder of Talis Biomedical?

Currently, no hedge funds are holding shares in TLIS

Compare

45 Followers

TLIS Stock Chart & Stats

$1.60

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$1.60

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$1.04 - $2.00

Previous CloseN/A

Volume40.00

Average Volume (3M)69.00

Market Cap

$50.70M

Enterprise ValueN/A

Total Cash (Recent Filing)$59.87M

Total Debt (Recent Filing)$18.80M

Price to Earnings (P/E)―

Beta1.28

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-28.02

Shares Outstanding1,822,820

10 Day Avg. Volume0

30 Day Avg. Volume69

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.20

Price to Sales (P/S)32.87

P/FCF Ratio-0.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Talis Biomedical News

Talis Biomedical Announces Board Shake-Up Amid Financial Struggles

Talis Biomedical (TLIS) has shared an update. Talis Biomedical Corporation is undergoing significant board restructuring, which includes the...

1y ago

TLIS

Talis Biomedical Secures Interim CFO Amidst Corporate Changes

The latest update is out from Talis Biomedical (TLIS). Talis Biomedical Corporation has struck a retention deal with...

2y ago

TLIS

Two new option listings and option delistings on February 26th

New option listings for February 26th include AMERICAN HEALTHCARE REIT INC (AHR) and Apollo Medical Holdings Inc (ASTH)....

2y ago

AHR

OCX

Talis Biomedical Ends Role of President Amid Reorganization

Talis Biomedical (TLIS) has released an update to notify the public and investors about its officers. Talis Biomedical...

2y ago

TLIS

Greenlight Capital buys DHT, exits Capri in Q3

David Einhorn’s Greenlight Capital disclosed in an SEC filing its holdings as of September 30, 2023. The fund’s...

2y ago

BHF

Talis Biomedical reports Q3 revenue $0.1M vs $0.8M last year

Cash and cash equivalents as of September 30, 2023, were $88.0 million. Published first on TheFly – the...

2y ago

TLIS

Talis Biomedical announces exploration of strategic alternatives

Talis Biomedical announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder...

2y ago

TLIS

TLIS Earnings this Week: How Will it Perform?

Talis Biomedical Corp. (TLIS) is scheduled to report 3rd quarter earnings on 11/13/2023. Regarding Q3 estimates, Wall Street...

2y ago

TLIS

Talis Biomedical price target raised to $5.00 from $0.35 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Talis Biomedical to $5.00 from $0.35 and keeps...

2y ago

TLIS

Talis Biomedical appoints Lukowiak as President, Chief Scientific Officer

Talis Biomedical announced that it has appointed Dr. Andrew Lukowiak as president and chief scientific officer, effective August...

2y ago

TLIS

Talis Biomedical announces new data on CT/NG/TV multiplex test

Talis Biomedical announced new data supporting the development of its planned chlamydia, gonorrhea and trichomonas, CT/NG/TV, and vaginal...

2y ago

TLIS

Talis Biomedical regains compliance with Nasdaq minimum bid price requirement

Talis Biomedical announced that it received written notice from The Nasdaq Stock Market dated July 20, 2023, that...

2y ago

TLIS

Talis Biomedical announces 1-or-15 reverse stock split

Talis Biomedical announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding...

2y ago

TLIS

Talis Biomedical Corp. Updates 1 Key Risk Factor

Talis Biomedical Corp. (TLIS) is a molecular diagnostics company focused on infectious disease testing at the point of...

4y ago

TLIS

TLIS FAQ

What was Talis Biomedical’s price range in the past 12 months?

Talis Biomedical lowest stock price was $1.04 and its highest was $2.00 in the past 12 months.

What is Talis Biomedical’s market cap?

Talis Biomedical’s market cap is $50.70M.

When is Talis Biomedical’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Talis Biomedical’s earnings last quarter?

Talis Biomedical released its earnings results on Aug 07, 2024. The company reported -$4.856 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.856.

Is Talis Biomedical overvalued?

According to Wall Street analysts Talis Biomedical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Talis Biomedical pay dividends?

Talis Biomedical does not currently pay dividends.

What is Talis Biomedical’s EPS estimate?

Talis Biomedical’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Talis Biomedical have?

Talis Biomedical has 1,822,820 shares outstanding.

What happened to Talis Biomedical’s price movement after its last earnings report?

Talis Biomedical reported an EPS of -$4.856 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Talis Biomedical?

Currently, no hedge funds are holding shares in TLIS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.